Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769-75, http://dx.doi.org/10.1210/jc.2006-1668.
Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377-82, http://dx.doi.org/10.1111/j.1365-2265.2009.03667.x.
Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab. 1990;71(6):1427-33, http://dx.doi.org/10.1210/jcem-71-6-1427.
Dworakowska D, Grossman AB. The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23(5):525-41, http://dx.doi.org/10.1016/j.beem.2009.05.004.
Vandeva S, Jaffrain-Rea ML, Daly AF, Tichomirowa M, Zacharieva S, Beckers A. The genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2010;24(3):461-76, http://dx.doi.org/10.1016/j.beem.2010.03.001.
Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23(5):543-54, http://dx.doi.org/10.1016/j.beem.2009.05.008.
Verloes A, Stevenaert A, Teh BT, Petrossians P, Beckers A. Familial acromegaly: case report and review of the literature. Pituitary. 1999;1(3-4):273-7, http://dx.doi.org/10.1023/A:1009958510378.
Valdes Socin H, Poncin J, Stevens V, Stevenaert A, Beckers A. Adenomes hypophysaires familiaux isoles non lies avec la mutation somatique NEM-1. Siuvi de 27 patients. Ann Endocrinol-Paris. 2000;61:301.
Valdes Socin H, Poncin J, Vanbelinghen J, Stevens V, Jaffrain-Rea M, Tamburrano G, et al. Familial isolated pituitary adenomas not related to the MEN1 syndrome. 5th European Congress of Endocrinology; 2001 9-13 june.
Valdes Socin H, Jaffrain Réa M, Tamburrano G, Cavagnini F, Cicarelli E, Colao A, et al. Familial isolated pituitary adenomas: clinical and molecular studies in 80 patients. The Endocrine Society's 84th Annual Meeting; 2002 19-22 june; San Francisco.
Beckers A. Familial isolated pituitary adenomas. J Intern Med. 2004;255(6):698.
Vasilev V, Daly AF, Petrossians P, Zacharieva S, Beckers A. Familial pituitary tumor syndromes. Endocr Pract. 2011;17(Suppl 3):41-6.
Chahal HS, Chapple JP, Frohman LA, Grossman AB, Korbonits M. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab. 2010;21(7):419-27, http://dx.doi.org/10.1016/j.tem.2010.02.007.
Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab. 2006;91(9):3316-23, http://dx.doi.org/10.1210/jc.2005-2671.
Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol. 2007;157(4):371-82, http://dx.doi.org/10.1530/EJE-07-0348.
Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab. 2008;93(6):2390-401, http://dx.doi.org/10.1210/jc.2007-2611.
Yamada S, Yoshimoto K, Sano T, Takada K, Itakura M, Usui M, et al. Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1997;82(1):239-42, http://dx.doi.org/10.1210/jc.82.1.239.
Gadelha MR, Prezant TR, Une KN, Glick RP, Moskal SF, 2nd, Vaisman M, et al. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J Clin Endocrinol Metab. 1999;84(1):249-56, http://dx.doi.org/10.1210/jc.84.1.249.
Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312(5777):1228-30, http://dx.doi.org/10.1126/science.1126100.
Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab. 2007;92(5):1891-6, http://dx.doi.org/10.1210/jc.2006-2513.
Lin BC, Sullivan R, Lee Y, Moran S, Glover E, Bradfield CA. Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. J Biol Chem. 2007;282(49):35924-32, http://dx.doi.org/10.1074/jbc.M705471200.
Raitila A, Lehtonen HJ, Arola J, Heliovaara E, Ahlsten M, Georgitsi M, et al. Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. Am J Pathol. 2010;177(4):1969-76, http://dx.doi.org/10.2353/ajpath.2010.100138.
Ozfirat Z, Korbonits M. AIP gene and familial isolated pituitary adenomas. Mol Cell Endocrinol. 2010;326(1-2):71-9, http://dx.doi.org/10.1016/j.mce.2010.05.001.
Trivellin G, Korbonits M. AIP and its interacting partners. J Endocrinol. 2011;210(2):137-55, http://dx.doi.org/10.1530/JOE-11-0054.
Oesch-Bartlomowicz B, Huelster A, Wiss O, Antoniou-Lipfert P, Dietrich C, Arand M, et al. Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways. Proc Natl Acad Sci U S A. 2005;102(26):9218-23, http://dx.doi.org/10.1073/pnas.0503488102.
Kazlauskas A, Poellinger L, Pongratz I. Evidence that the co-chaperone p23 regulates ligand responsiveness of the dioxin (Aryl hydrocarbon) receptor. J Biol Chem. 1999;274(19):13519-24, http://dx.doi.org/10.1074/jbc. 274.19.13519.
Kazlauskas A, Poellinger L, Pongratz I. The immunophilin-like protein XAP2 regulates ubiquitination and subcellular localization of the dioxin receptor. J Biol Chem. 2000;275(52):41317-24, http://dx.doi.org/10.1074/jbc.M007765200.
Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen JF, et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer. 2009;16(3):1029-43, http://dx.doi.org/10.1677/ERC-09-0094.
Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem. 2003;278(35):33351-63, http://dx.doi.org/10.1074/jbc.M303269200.
de Oliveira SK, Hoffmeister M, Gambaryan S, Muller-Esterl W, Guimaraes JA, Smolenski AP. Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J Biol Chem. 2007;282(18):13656-63, http://dx.doi.org/10.1074/jbc.M610942200.
Horvath A, Stratakis CA. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev Endocr Metab Disord. 2008;9(1):1-11, http://dx.doi.org/10.1007/s11154-007-9066-9.
Vargiolu M, Fusco D, Kurelac I, Dirnberger D, Baumeister R, Morra I, et al. The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. J Clin Endocrinol Metab. 2009;94(7):2571-8, http://dx.doi.org/10.1210/jc.2008-1980.
Jaffrain-Rea M-L, Daly AF, Angelini M, Petrossians P, Bours V, Beckers A. Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications. Exp Rev Endocrinol Metab. 2011;6(2):195-214, http://dx.doi.org/10.1586/eem.10.87.
Barlier A, Vanbellinghen JF, Daly AF, Silvy M, Jaffrain-Rea ML, Trouillas J, et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J Clin Endocrinol Metab. 2007;92(5):1952-5, http://dx.doi.org/10.1210/jc.2006-2702.
Igreja S, Chahal HS, King P, Bolger GB, Srirangalingam U, Guasti L, et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat. 2010;31(8):950-60, http://dx.doi.org/10.1002/humu.21292.
Georgitsi M, Heliovaara E, Paschke R, Kumar AV, Tischkowitz M, Vierimaa O, et al. Large genomic deletions in AIP in pituitary adenoma predisposition. J Clin Endocrinol Metab. 2008;93(10):4146-51, http://dx.doi.org/10.1210/jc.2008-1003.
Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, Barlier A, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95(11): E373-83, http://dx.doi.org/10.1210/jc.2009-2556.
Toledo RA, Lourenco DM Jr., Toledo SP. Familial isolated pituitary adenoma: evidence for genetic heterogeneity. Front Horm Res. 2010;38:77-86, http://dx.doi.org/10.1159/000318497.
Naves LA, Daly AF, Vanbellinghen JF, Casulari LA, Spilioti C, Magalhaes AV, et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur J Endocrinol. 2007;157(4):383-91, http://dx.doi.org/10.1530/EJE-07-0533.
Tichomirowa MA, Bariler A, Daly AF, Jaffrain-Rea M-L, Ronchi CL, Yaneva M, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol. 2011;165(4):509-15, http://dx.doi.org/10.1530/EJE-11-0304.
